These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 26869192)

  • 1. Improvement of Pediatric Drug Development: Regulatory and Practical Frameworks.
    Tsukamoto K; Carroll KA; Onishi T; Matsumaru N; Brasseur D; Nakamura H
    Clin Ther; 2016 Mar; 38(3):574-81. PubMed ID: 26869192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Industry Perspective of Pediatric Drug Development in the United States: Involvement of the European Union Countries.
    Onishi T; Tsukamoto K; Matsumaru N; Waki T
    Ther Innov Regul Sci; 2018 Jan; 52(1):49-56. PubMed ID: 29714619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. European Union pediatric legislation jeopardizes worldwide, timely future advances in the care of children with cancer.
    Rose K
    Clin Ther; 2014 Feb; 36(2):163-77. PubMed ID: 24529288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timing of Pediatric Drug Approval and Clinical Evidence Submitted to Regulatory Authorities: International Comparison Among Japan, the United States, and the European Union.
    Hirota S; Yamaguchi T
    Clin Pharmacol Ther; 2020 Nov; 108(5):985-994. PubMed ID: 31869436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orphan Medicines for Pediatric Use: A Focus on the European Union.
    Bolislis WR; Corriol-Rohou S; Hill-Venning C; Hoogland H; Joos A; King D; Kitcatt V; Le Visage G; Kühler TC
    Clin Ther; 2019 Dec; 41(12):2630-2642. PubMed ID: 31704041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Drug Characteristics for Implementing Multiregional Clinical Trials Including Japan.
    Rokuda M; Matsumaru N; Tsukamoto K
    Clin Ther; 2018 Feb; 40(2):284-295. PubMed ID: 29361305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moving toward a paradigm shift in the regulatory requirements for pediatric medicines.
    Chin WW; Joos A
    Eur J Pediatr; 2016 Dec; 175(12):1881-1891. PubMed ID: 27646479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Drugs for Rare Diseases in Children.
    Rose K
    Clin Ther; 2017 Feb; 39(2):246-252. PubMed ID: 28161117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do the European Medicines Agency Decisions Hurt Pediatric Melanoma Patients?
    Rose K; Walson PD
    Clin Ther; 2017 Feb; 39(2):253-265. PubMed ID: 28159363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three years of paediatric regulation in the European Union.
    Olski TM; Lampus SF; Gherarducci G; Saint Raymond A
    Eur J Clin Pharmacol; 2011 Mar; 67(3):245-52. PubMed ID: 21286912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pediatric Off-Label and Unlicensed Drug Use and Its Implications.
    Gore R; Chugh PK; Tripathi CD; Lhamo Y; Gautam S
    Curr Clin Pharmacol; 2017; 12(1):18-25. PubMed ID: 28322168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Novel Pharmaceutical Agents for Alzheimer's Disease: The Impact of Regulatory Initiatives in Japan and the United States.
    Tsukamoto K
    Clin Ther; 2015 Aug; 37(8):1652-60. PubMed ID: 25801940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of Pediatric Drug Approval Lag in Japan.
    Ueyama E; Kaneko M; Narukawa M
    Ther Innov Regul Sci; 2021 Mar; 55(2):336-345. PubMed ID: 32959206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The European Regulation on medicines for paediatric use.
    Dunne J
    Paediatr Respir Rev; 2007 Jun; 8(2):177-83. PubMed ID: 17574163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory approval pathways for anticancer drugs in Japan, the EU and the US.
    Nagai S; Ozawa K
    Int J Hematol; 2016 Jul; 104(1):73-84. PubMed ID: 27084259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delays in completion and results reporting of clinical trials under the Paediatric Regulation in the European Union: A cohort study.
    Hwang TJ; Tomasi PA; Bourgeois FT
    PLoS Med; 2018 Mar; 15(3):e1002520. PubMed ID: 29494592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The economics of pediatric formulation development for off-patent drugs.
    Milne CP; Bruss JB
    Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioequivalence Evaluations of Generic Dry Powder Inhaler Drug Products: Similarities and Differences Between Japan, USA, and the European Union.
    Kuribayashi R; Yamaguchi T; Sako H; Takishita T; Takagi K
    Clin Pharmacokinet; 2017 Mar; 56(3):225-233. PubMed ID: 27461251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.